We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hinge Health Inc. (HNGE) Up 17.2% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Hinge Health Inc. (HNGE - Free Report) . Shares have added about 17.2% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Hinge Health Inc. due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for Hinge Health Inc. before we dive into how investors and analysts have reacted as of late.
HNGE Q4 Earnings & Sales Beat Estimates
Hinge Health reported earnings per share of 49 cents in fourth-quarter 2025, beating the Zacks Consensus Estimate of 42 cents by 16.7%.
For full-year 2025, GAAP net loss per share was $7.77, significantly wider compared to 86 cents in the year-ago period, primarily reflecting IPO-related and stock-based compensation impacts. Management highlighted that the company expects to be GAAP profitable in 2026, building on fourth-quarter’s profitability.
Revenue Discussion
Fourth-quarter revenue rose 46% year over year to $170.7 million, beating the Zacks Consensus Estimate by 8.5%. The year-over-year growth of 45.6% was driven by strong yield improvement and expanding contracted lives.
For full-year 2025, revenue climbed 51% to $587.9 million compared with $390.4 million in 2024. LTM calculated billings reached $671 million, up 44% year over year.
Hinge Health ended 2025 with approximately 24.6 million contracted lives across more than 2,800 clients, up 24% year over year. LTM average eligible lives were 20.1 million, driving 783,000 members, a 47% increase from 2024. Client retention stood at 97%, while net dollar retention exceeded 110%.
Margin Discussion
Gross margin expanded to 85% in fourth quarter from 82% in the prior-year quarter. Operating margin improved to 28% from 18% a year ago. For full-year 2025, operating margin was 20%, up from negative 7% in 2024.
Financial Position
Free cash flow was $62 million in fourth quarter, representing a 36% margin. Full-year free cash flow reached $180 million versus $45 million in 2024. Cash and equivalents stood at $479 million at year-end.
2026 Outlook
For first-quarter 2026, Hinge Health expects revenue of $171-$173 million and adjusted operating income of $30-$32 million. For full-year 2026, revenue is projected at $732-$742 million, implying 25% growth at midpoint, with operating income of $151-$156 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
The consensus estimate has shifted 118.18% due to these changes.
VGM Scores
Currently, Hinge Health Inc. has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Hinge Health Inc. has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Hinge Health Inc. (HNGE) Up 17.2% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Hinge Health Inc. (HNGE - Free Report) . Shares have added about 17.2% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Hinge Health Inc. due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for Hinge Health Inc. before we dive into how investors and analysts have reacted as of late.
HNGE Q4 Earnings & Sales Beat Estimates
Hinge Health reported earnings per share of 49 cents in fourth-quarter 2025, beating the Zacks Consensus Estimate of 42 cents by 16.7%.
For full-year 2025, GAAP net loss per share was $7.77, significantly wider compared to 86 cents in the year-ago period, primarily reflecting IPO-related and stock-based compensation impacts. Management highlighted that the company expects to be GAAP profitable in 2026, building on fourth-quarter’s profitability.
Revenue Discussion
Fourth-quarter revenue rose 46% year over year to $170.7 million, beating the Zacks Consensus Estimate by 8.5%. The year-over-year growth of 45.6% was driven by strong yield improvement and expanding contracted lives.
For full-year 2025, revenue climbed 51% to $587.9 million compared with $390.4 million in 2024. LTM calculated billings reached $671 million, up 44% year over year.
Hinge Health ended 2025 with approximately 24.6 million contracted lives across more than 2,800 clients, up 24% year over year. LTM average eligible lives were 20.1 million, driving 783,000 members, a 47% increase from 2024. Client retention stood at 97%, while net dollar retention exceeded 110%.
Margin Discussion
Gross margin expanded to 85% in fourth quarter from 82% in the prior-year quarter. Operating margin improved to 28% from 18% a year ago. For full-year 2025, operating margin was 20%, up from negative 7% in 2024.
Financial Position
Free cash flow was $62 million in fourth quarter, representing a 36% margin. Full-year free cash flow reached $180 million versus $45 million in 2024. Cash and equivalents stood at $479 million at year-end.
2026 Outlook
For first-quarter 2026, Hinge Health expects revenue of $171-$173 million and adjusted operating income of $30-$32 million. For full-year 2026, revenue is projected at $732-$742 million, implying 25% growth at midpoint, with operating income of $151-$156 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
The consensus estimate has shifted 118.18% due to these changes.
VGM Scores
Currently, Hinge Health Inc. has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Hinge Health Inc. has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.